Anti-Thymocyte Globulin (Equine)
ATGAM
- Dosage form
- Tablet
- Available strengths
- 50 mg/mL
- Drug class
- Immunosuppressant (polyclonal anti-thymocyte antibody)
- Common brand
- ATGAM
Clinical overview. Anti-thymocyte globulin (equine), sold as ATGAM, is an intravenous immunosuppressant derived from horse plasma, used to treat aplastic anemia and to prevent or treat rejection after kidney transplantation. It is given as a slow infusion in a hospital setting, typically alongside other immunosuppressants, with skin testing recommended beforehand to screen for hypersensitivity. Chills, fever, and skin reactions are common, while anaphylaxis, severe blood count suppression, and serum sickness are important risks requiring close monitoring during and after each infusion.
Indication
Common therapeutic uses
- Anti-thymocyte globulin (equine) is used to reduce peripheral T-lymphocyte function in patients where this is clinically desirable.
- It is used to treat aplastic anemia.
- It is used to treat acute renal allograft rejection episodes together with conventional therapy, or to delay the onset of a first rejection episode when combined with other immunosuppressive therapy.
Pregnancy
Risk assessment and monitoring considerations
- There are no adequate and well-controlled studies of anti-thymocyte globulin (equine) in pregnant women, and pregnancy outcomes with its use cannot be determined from available data.
- It should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus.
- Animal studies have shown reproductive toxicity, though the drug was not found to be teratogenic in rats or monkeys.
- Women of childbearing potential should use effective contraception during treatment and for at least 10 weeks after stopping therapy.
Breastfeeding
Infant exposure considerations
- It is not known whether anti-thymocyte globulin (equine) is excreted into human milk.
- Because many drugs are excreted in breast milk and serious reactions are possible in a nursing infant, a decision should be made whether to discontinue breastfeeding or discontinue the drug, taking into account the importance of treatment to the mother.
Geriatrics
Dosing and tolerability considerations
- Clinical experience in a limited number of patients 65 years of age and older has not identified differences in response compared with younger patients.
- Dosing in elderly patients should be selected with caution, generally starting at the low end of the dosage range, reflecting a greater likelihood of reduced hepatic, renal, or cardiac function and concurrent illness or other medications in this age group.
Pediatrics
Use in children and adolescents
- Experience in children is limited, but anti-thymocyte globulin (equine) has been administered safely to a small number of pediatric renal, liver, and bone marrow transplant recipients and aplastic anemia patients at doses comparable to those used in adults.
Dosage & Administration
Practical dosing and administration
- For delaying renal allograft rejection, the recommended dose is 15 mg/kg daily for 14 days, then every other day for a total of 21 doses over 28 days, with the first dose given within 24 hours before or after transplant.
- For treatment of acute renal allograft rejection, the recommended dose is 10 to 15 mg/kg daily for 14 days, with additional alternate-day doses up to a total of 21 doses.
- For aplastic anemia, the typical regimen is 10 to 20 mg/kg daily for 8 to 21 doses, usually given together with ciclosporin, and platelet transfusions may be needed to manage treatment-related thrombocytopenia.
- For liver and heart transplant recipients, reported dosing ranges from 5 to 15 mg/kg daily, with treatment duration and total number of doses individualized to the patient.
- For bone marrow transplant patients, doses of 7 to 20 mg/kg have been used for 3 to 14 doses, either before transplant for pre-conditioning, or after transplant for prevention or treatment of graft-versus-host disease.
- Skin testing with epicutaneous and intradermal ATGAM is strongly recommended before the first infusion to assess for hypersensitivity, though a negative test does not rule out a later allergic reaction.
- Dilute the total daily dose in an inverted bottle or bag of sterile 0.9% sodium chloride or a glucose/sodium chloride solution to a concentration of 1 to 4 mg/mL, and infuse through an in-line filter over no less than 4 hours.
- Do not administer ATGAM to a patient who has had a severe systemic reaction to a previous dose of ATGAM or another equine gamma globulin product.
- Premedication with corticosteroids and antihistamines before infusion, and continued monitoring for at least 24 hours afterward, is recommended to reduce the risk and severity of infusion reactions.
- If a dose is missed, contact the treating healthcare professional, since ATGAM is administered in a hospital setting.
- Specific dosing studies have not been performed in patients with hepatic or renal impairment.
Overdose
Recognizing and responding to overdose
If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.
- Because this product is a biologic, the dose that would produce toxicity is expected to vary from patient to patient.
- The highest single daily dose reported, about seven times the usual recommended amount, was not associated with signs of acute toxicity in the patient who received it.
- Patients who received extended or repeated courses of therapy have not shown increased toxicity, but close monitoring is recommended after any suspected overdose.
Common side effects
Frequently reported tolerability concerns
- Chills are very common.
- Fever is very common.
- Skin reactions, including itching (pruritus), rash, hives (urticaria), and wheal-and-flare reactions, are common.
- Low white blood cell count (leukopenia) is common.
- Low platelet count (thrombocytopenia) is common.
- Diarrhea may occur.
- Nausea may occur.
- Vomiting may occur.
- Mouth sores (stomatitis) may occur.
- Chest pain may occur.
- Infusion site pain may occur.
- Joint pain (arthralgia) may occur.
- Back pain may occur.
- Headache may occur.
- Shortness of breath (dyspnea) may occur.
- Night sweats may occur.
- Low blood pressure (hypotension) may occur.
Serious side effects
Findings that may require urgent assessment
Serious side effects require immediate discussion with the prescriber or emergency care.
- Anaphylaxis can occur and can be life-threatening when ATGAM is given intravenously; patients should be monitored during infusion and for at least 24 hours afterward.
- Serious, unremitting thrombocytopenia or leukopenia may develop and can require dose reduction or discontinuation.
- Serum sickness-like symptoms, including rash, joint pain, fever, and chills, can occur, particularly in patients with aplastic anemia.
- Fulminant hemolysis has been reported rarely and may require transfusion or supportive treatment.
- Cytokine release syndrome, which can be fatal, is a potential risk based on the drug's mechanism of action.
- Serious immune-mediated reactions, including anaphylaxis and infusion-related reactions, have been reported.
- Opportunistic bacterial and fungal infections, including sepsis, are very common due to the drug's immunosuppressive effect.
- Reactivation of viral infections, including cytomegalovirus, Epstein-Barr virus, and herpes simplex virus, can occur.
- Chemical phlebitis can occur when ATGAM is infused through a peripheral vein.
- Because this product is derived from horse plasma, there is a possibility it may transmit infectious agents, including unknown or emerging pathogens, despite viral inactivation steps in manufacturing.
- Abnormal liver and kidney function test results have been observed in treated patients.
- Seek urgent medical attention for hives, difficulty breathing, chest or flank pain, high fever, or signs of a severe infection during or after treatment.
Use with caution
Situations requiring closer assessment
- Use with caution in patients undergoing repeat courses of ATGAM, observing closely for allergic reactions.
- Use with caution when reducing the dose of concomitant corticosteroids or other immunosuppressants, since previously masked reactions to ATGAM may appear.
- Use with caution in patients with aplastic anemia, who may require prophylactic platelet transfusions due to a higher risk of thrombocytopenia.
- Monitor closely for signs of leukopenia, thrombocytopenia, or infection throughout treatment, since ATGAM is usually given with corticosteroids and antimetabolites.
- Vaccination is not recommended during ATGAM therapy, since live vaccines may not replicate successfully and vaccine effectiveness may be reduced.
- Use caution when driving or operating machinery, since dizziness, confusion, syncope, or convulsions have been reported.
- Do not dilute ATGAM in dextrose solution alone or in highly acidic infusion solutions, due to the risk of precipitation or instability.
- Only physicians experienced in immunosuppressive therapy and management of transplant patients should prescribe and administer ATGAM, in facilities equipped with adequate laboratory and supportive resources.
- Keep emergency medications, including epinephrine, antihistamines, and corticosteroids, at the patient's bedside throughout the infusion.
Contraindications
Situations where therapy may be inappropriate
- Contraindicated in patients with known hypersensitivity to ATGAM or to any ingredient in the formulation, including any non-medicinal ingredient or component of the container.
- Contraindicated in patients who have had a severe systemic reaction during a previous administration of ATGAM or any other equine gamma globulin preparation.
Drug interactions
Clinically relevant combinations
- Formal drug interaction studies have not been conducted with ATGAM.
- Reducing the dose of concomitant corticosteroids or other immunosuppressants may unmask previously suppressed reactions to ATGAM, requiring closer monitoring.
- Concomitant vaccination is not recommended, since ATGAM may reduce the effectiveness of live vaccines.
- Interactions with other drugs beyond concomitant immunosuppressants have not been established.
Food interactions
Meal-related administration
- Interactions with food have not been established for this intravenous product.
Time of administration
Practical scheduling
- ATGAM is given as a slow intravenous infusion over at least 4 hours in a hospital or clinical setting, on a schedule set by the treating physician rather than tied to a specific time of day.
Storage
Product handling
- Store ampoules refrigerated at 2°C to 8°C; do not freeze.
- Keep the ampoule in its carton to protect from light.
- Once diluted, the solution should be stored at room temperature and used within 24 hours, including infusion time.
Patient take-away
Key counselling points for a quick closing summary
- ATGAM is an intravenous immunosuppressant given in hospital to treat aplastic anemia or to prevent or treat rejection after a kidney transplant.
- Skin testing is usually done before your first dose to check for allergy risk, and you will be closely monitored during and for 24 hours after each infusion for signs of a reaction.
- Chills, fever, and skin reactions are common, but seek immediate help for hives, trouble breathing, chest or flank pain, or signs of serious infection.
- Tell your healthcare team if you are pregnant, breastfeeding, or planning to become pregnant, and use effective contraception during and for 10 weeks after treatment.
References
Source material and product information
For professional reference. Confirm patient-specific decisions against the current approved product monograph and applicable clinical guidance.